<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116523/" ref="ordinalpos=490&amp;ncbi_uid=6458773&amp;link_uid=PMC4116523" image-link="/pmc/articles/PMC4116523/figure/F2/" class="imagepopup">Figure 2. The effect of candidate peptides on VEGFR-3 phosphorylation and VEGFR-3-mediated <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>.  From: Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects. </a></div><br /><div class="p4l_captionBody">(<b>A</b> and <b>B</b>) Effects of candidate peptides on VEGFR-3-mediated signaling pathway. A549 (<b>A</b>) and HEK293T/VEGFR-3 (<b>B</b>) cells were treated with rhVEGF-C in the absence or presence of candidate peptides or soluble VEGFR-3 (sR3; as the inhibitor for VEGF-C-induced VEGFR-3 activation). (<b>C</b> and <b>D</b>) Dose-dependent effects of P5 or P6 peptides on VEGFR-3-mediated signaling pathway. A549 (<b>C</b>) and HEK293T/VEGFR-3 (<b>D</b>) cells were stimulated with rhVEGF-C with increased concentrations of P5 or P6 peptides. Cell lysates were harvested and subjected to SDS-PAGE followed by western blot analysis with anti–p-tyr1063/1068-VEGFR-3 and anti–p-src antibodies.</div></div>